Case studies

"We rely on LexisNexis to give us a definitive answer, quickly and reliable every time so that we can be confident in the advice we use to help our clients."

Shelter

Access all 9 documents on Molecule

GET ACCESS NOW

GLOSSARY

Molecule definition

Published by a LexisNexis Energy expert

What does Molecule mean?

The smallest portion of a substance that can exist by itself and retain the properties of the substance. Molecules consist of multiple atoms and a particular molecule has a specific number of atoms arranged in a specific way. Water is a molecule consisting of two hydrogen atoms and one oxygen atom – the hydrogen atoms are bound to opposite sides of the oxygen atom with an angle of about 104.5? between the two hydrogen atoms.

Speed up all aspects of your legal work with tools that help you to work faster and smarter. Win cases, close deals and grow your business–all whilst saving time and reducing risk.

Life sciences glossary E–H

Life sciences glossary E–H A–B | C–D | I–N | O–P | Q–V. Early access to medicines scheme Under the early access to medicines scheme (EAMS), the Medicines and Healthcare products Regulatory Agency (MHRA) grants patients with life-threatening or seriously debilitating conditions access to medicines which do not yet have marketing authorisation (MA) (or are not licensed to treat that indication yet) but where there is a clear unmet medical need. For more information, see Practice Notes: UK marketing authorisations for medicinal products—Early access to medicines scheme (EAMS)—exemption and Unlicensed medicinal products and off-label use of medicinal products—Early access to medicines scheme (EAMS)—UK regime and MHRA guidance: Apply for the early access to medicines scheme (EAMS). EFPIA Code The EFPIA Code is a collection of industry, self-governance ethical rules of conduct that govern the promotion of prescription-only medicines (POMs) by all European Federation of Pharmaceutical Industries and Associations (EFPIA) member companies when interacting with healthcare professionals (HCPs) healthcare organisations (HCOs), patients’ organisations (POs) and the general public. This includes pharmaceutical...

Case T- 691/14 Servier v Commission et al (pay–for–delay) [Archived]

Case T- 691/14 Servier v Commission et al (pay–for–delay) [Archived] ARCHIVED—this achieved case hub reflects the position at the date of the decision of 12 December 2018; it is no longer maintained. NOTE—appeals lodged before the Court of Justice in Cases C- 144/19 P, C- 151/19 P, C- 164/19 P, C- 166/19 P, C- 176/19 P, C- 197/19 P, C- 198/19 P, C- 201/19 P and C- 207/19 P See further: timeline and commentary. Case facts Outline Appeals to the General Court in seeking annulment and/or reductions in the level of fines imposed regarding the Commission’s decision of 9 June 2014 finding infringements of Article 101 and Article 102 insofar as they relate to Servier and imposing fines totalling €427.7m on Servier and five producers of generic drugs to delay the entry of perindopril. Outcome On 12 December 2018, the General Court issued its judgments in Cases T- 691/14 Servier v Commission, T- 677/14 Biogaran v Commission, T- 679/14 Teva UK and Others v...

Discover our 9 Practice Notes on Molecule